Bioventus Inc. (BVS), a medical device company, will report its financial results for the fourth quarter and full year 2024 before the market opens on March 11, 2025.
The company expects net sales for the full year 2024 to be in the range of $562 million to $567 million. Net sales were $512.3 million in 2023.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com